文献速递消化道肿瘤放疗放疗物理与技术

影像引导自适应腔内近距离放疗在直肠癌非手术管理中的应用

Image Guided Adaptive Endorectal Brachytherapy in the Nonoperative Management of Patients With Rectal Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-08-30

这项注册研究纳入94例不适合手术的直肠癌患者,先接受40 Gy/16次盆腔外照射,再接受3次每周10 Gy影像引导自适应近距离放疗推量(总30 Gy/3次)。中位随访1.9年,完全临床缓解率为86.2%,2年局部控制率71.5%,2年总生存率63.6%,毒性可控。

要点

  • 不适合手术的直肠癌患者接受外照射40 Gy/16次后行3次10 Gy影像引导自适应近距离放疗推量。
  • 完全临床缓解率86.2%,肿瘤再生长比例13.6%,2年局部控制率71.5%。
  • 2年总生存率63.6%,晚期出血需铁剂、输血或氩气等离子治疗者占12.8%。

核心结论

  • 在老年医学上不适合手术且肿瘤未加选择的直肠癌患者中,影像引导自适应腔内近距离放疗推量可使高比例患者达到完全临床缓解,毒性可控。

研究设计与样本

  • 注册研究,纳入94例不适合手术的直肠癌患者,中位年龄81.1岁。
  • 患者接受40 Gy/16次盆腔外照射,随后接受3次每周10 Gy影像引导自适应近距离放疗推量,总量30 Gy/3次。

主要发现

  • 中位随访1.9年,完全临床缓解率为86.2%,肿瘤再生长比例为13.6%。
  • 局部复发累积发生率1年为2.7%,2年为16.8%;计入缓解与未缓解者,2年局部控制率为71.5%。
  • 2年总生存率为63.6%。
  • 急性直肠1至2级毒性见于全部患者;12.8%患者出现晚期出血,需铁剂替代、输血或氩气等离子治疗。

关键数值与推荐

  • 外照射剂量为40 Gy/16次,近距离放疗推量为3次每周10 Gy,总剂量30 Gy/3次。
  • 完全临床缓解率86.2%,肿瘤再生长比例13.6%,1年局部复发累积发生率2.7%,2年16.8%。
  • 2年局部控制率71.5%,2年总生存率63.6%,晚期出血需干预者占12.8%。

临床怎么用

  • 对于不适合手术且拒绝手术的直肠癌患者,可考虑外照射后行影像引导自适应腔内近距离放疗推量以实现器官保留。
  • 治疗中需关注急性直肠1至2级毒性及晚期出血风险,必要时给予铁剂、输血或氩气等离子治疗。

局限性

  • 本研究为注册研究,非随机对照设计。
  • 随访时间中位仅1.9年,长期疗效与毒性数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Organ preservation or nonoperative management of rectal cancer is of growing interest. Image guided adaptive endorectal brachytherapy is a radiation dose escalation modality: we explored its role in elderly patients unfit for surgery and patients refusing surgery. METHODS AND MATERIALS: In this registry study, patients with rectal cancer who were ineligible for surgery received 40 Gy in 16 fractions of pelvic external beam radiation therapy. They subsequently received 3 weekly image guided adaptive brachytherapy boosts of 10 Gy to the residual tumor, for a total of 30 Gy in 3 fractions. Complete clinical response (cCR) and local control were the primary endpoints. RESULTS: 94 patients were included; the median age was 81.1 years. With a median follow-up of 1.9 years, the proportion of cCR was 86.2%, the tumor regrowth proportion was 13.6%, and the cumulative incidence of local relapse was 2.7% at 1 year and 16.8% at 2 years. When considering responders and nonresponders, the 2-year local control was 71.5%. The overall survival at 2 years was 63.6%. Acute rectal grade 1 to 2 toxicity included all patients: 12.8% of patients had late bleeding requiring iron replacement, blood transfusions, or argon plasma therapy. CONCLUSIONS: Results of this registry study, evaluating radiation dose escalation for elderly medically unfit patients with unselected tumors, reveal that a high proportion of patients achieved cCR with a manageable toxicity profile. This technology will likely contribute to the challenging nonoperative management paradigm of rectal cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Garant A, Magnan S, Devic S, et al. Image Guided Adaptive Endorectal Brachytherapy in the Nonoperative Management of Patients With Rectal Cancer. Int J Radiat Oncol Biol Phys. 2019. PMID: 31476417. doi:10.1016/j.ijrobp.2019.08.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。